Drugs / SHR-4849
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06443489 | Jun 2024 → Dec 2026 expected | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07268040 | Dec 2025 → Dec 2028 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07028281 | Jul 2025 → Dec 2028 expected | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-09-16 | Jiangsu HengRui Medicine Co., Ltd. | Results 2025 WCLC口头报告｜恒瑞创新药SHR-4849在复发性小细胞肺癌患者中的首次人体Ⅰ期研究结果披露 hengrui.com ↗
结果显示 [1] ，SHR-4849在复发性小细胞肺癌患者中展现出可耐受且可控的安全性特征。 |
| 2025-09-07 | IDEAYA Biosciences | Results IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer ideayabio.com ↗
80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg expansion dose of IDE849 |
| 2025-05-06 | IDEAYA Biosciences | Regulatory IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors ideayabio.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-4849 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06443489 ↗ |